Target RM2.10 (Short Term: Trading Buy)
We cease coverage on Adventa as its glove business has been taken private by the founding Lim family for RM2.10/share. Adventa intends to remain listed on Bursa and will retain RM0.40/share to build an integrated healthcare company. Our last rating was Trading Buy. Adventa will focus on building its home dialysis business, which in Malaysia is valued at RM800m annually and is growing by 12% p.a. according to Adventa. For exposure to the rising demand for examination gloves, we recommend Hartalega.
yanxuan8
On EX-date 4th Jan 2013, ADVENTA will trade above 30 sen, in line with CIMB's target price of RM2.10! If looking at the current price of RM1.91, our cost is only 21 sen (after deducting RM1.70 of special dividend and capital repayment), very cheap!
2012-12-31 15:25